Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 17/20 | 0.52 |
| ▸ | CDK1 | P06493 | 15/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 15/20 | 0.52 |
| ▸ | CCNT1 | O60563 | 14/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 14/20 | 0.52 |
| ▸ | CDK9 | P50750 | 14/20 | 0.52 |
| ▸ | CDK7 | P50613 | 13/20 | 0.52 |
| ▸ | CCNH | P51946 | 13/20 | 0.52 |
| ▸ | CDK4 | P11802 | 12/20 | 0.52 |
| ▸ | CCND1 | P24385 | 12/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.43 |
| ▸ | IGF1R | P08069 | 2/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11295191 | 0.83 | CDK2 (0.74) | CDK2CDK1CCNB1CCNT1CCNE1 | |
| SCHEMBL11294704 | 0.81 | NPC1 (0.43) | CDK2CDK1CCNB1CCNT1CCNE1 | |
| SCHEMBL11296091 | 0.78 | CDK2 (0.58) | CDK2CDK1CCNB1CCNT1CCNE1 | |
| SCHEMBL11302476 | 0.77 | CDK2 (0.54) | CDK2CDK1CCNB1CCNT1CCNE1 | |
| SCHEMBL13373308 | 0.77 | CDK2 (0.42) | CDK2CDK1CCNB1CCNT1CCNE1 | |
| SCHEMBL11295245 | 0.77 | CDK2 (0.55) | CDK2CDK1CCNB1CCNT1CCNE1 | |
| SCHEMBL13591930 | 0.76 | CDK2 (0.53) | CDK2CDK1CCNB1CCNT1CCNE1 | |
| SCHEMBL11297358 | 0.76 | CDK2 (0.62) | CDK2CDK1CCNB1CCNT1CCNE1 | |
| SCHEMBL11295831 | 0.76 | IKBKB (0.64) | CDK2CDK1CCNB1CCNT1CCNE1 | |
| SCHEMBL11296138 | 0.75 | CDK2 (0.53) | CDK2CDK1CCNB1CCNT1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288400-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288400-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120183577-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120183577-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| US-8017619-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017619-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-13 | — | — | US | disclosed |
| US-20100280026-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100280026-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-04 | — | — | US | disclosed |
| US-7700609-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700609-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280026-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K6 | CDK2 65/4885CDK1 73/4885CCNB1 967/4885 |
| US-20120183577-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K6 | CDK2 65/4885CDK1 73/4885CCNB1 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.